Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Tilray to Collaborate With Sandoz on Medical Cannabis Products Across the World

By Mike Botta | December 18, 2018

Tilray Inc. announced Tuesday that its Tilray Canada Ltd. subsidiary has entered into a global “framework agreement” to collaborate with Sandoz AG, part of Novartis group, to increase availability of high quality medical cannabis products across the world.

Shares of Tilray were surging in Tuesday afternoon trading after the announcement.

Under the deal, Tilray and Sandoz’s Canadian arm plan to jointly operate in jurisdictions where cannabis is or will be approved for medical purposes.

The agreement, which builds upon an existing alliance between the two companies, also allows the companies to potentially collaborate in such areas as co-branding certain non-smokable/non-combustible products and developing new medical cannabis products.

Tilray was the first licensed medical cannabis producer in North America to obtain current Good Manufacturing Practice (cGMP) certification in accordance with the European Medicines Agency’s (EMA) standards.

Under the framework agreement: 

  • Sandoz AG may support the global commercialization of Tilray’s non-smokable/non-combustible medical cannabis products

  • Tilray and Sandoz AG may co-brand certain non-smokable/non-combustible products

  • Tilray may supply non-smokable/non-combustible medical cannabis products and license rights to and from Sandoz AG in relation to such products; both companies also may partner to leverage best-in-class knowledge to educate pharmacists and physicians about medical cannabis products

  • Tilray and Sandoz AG may collaborate to develop new medical cannabis products.

Tilray’s stock jumped more than 15 percent to $76.05 in afternoon trading Tuesday, while Novartis AG shares dipped 25 cents to $85.51.

The company’s operation in Nanaimo, BC, is licenced to produce dried cannabis and cannabis extracts, including both bottled oil and capsules, for medical purposes, according to Canada’s CTV News. It also has a licenced facility in Enniskillen, ON, and is seeking a licence for a processing facility in London, ON.

Tilray has products available in 12 countries and operations in Australia, New Zealand, Canada, Germany, Latin America, and Portugal.

(Source: Tilray Inc.; Associated Press; CTV News)

Related Articles Read More >

President Joe Biden
Biden to order analysis of pharma supply chain
5 takeaways from the latest White House COVID-19 response team briefing
Pfizer-BioNTech vaccine
Pfizer vaccine stable at standard freezer temps, effective with single dose
Biden
Why Big Tech is offering Biden help with COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards